KEY POINTS
-
Lilly’s $3.5 billion project represents one of Pennsylvania’s largest recent life sciences investments.
-
The new facility targets next-generation injectable medicines, leveraging AI and data-driven technologies in U.S. pharmaceutical manufacturing.
-
The initiative follows Lilly’s $6B Huntsville, AL announcement in December, part of the company’s broader initiative to expand domestic medicine manufacturing.
Eli Lilly and Company announced the selection of Lehigh Valley, Pennsylvania, for its $3.5 billion injectable medicine manufacturing facility, according to a company statement last week. The investment is projected to generate more than 2,800 jobs, including 2,000 in construction and 850 permanent roles.
Strengthening the US Pharmaceutical Supply Chain
Lilly’s $3.5 billion Pennsylvania commitment follows its December 2025 announcement of a $6 billion investment in a manufacturing complex in Huntsville, Alabama.
The Lilly announcement is part of the company’s broader effort to expand its U.S. manufacturing presence to strengthen the domestic pharmaceutical supply, enhance resilience, and reduce dependencies on international sources for critical medicines.
Since 2020, Lilly’s capital expansion commitments have totaled more than $50 billion and include: new sites in Alabama, Pennsylvania, Texas, Virginia, North Carolina, and Indiana; development of the new Lilly Medicine Foundry in Indiana; site expansions in Puerto Rico and at the Lilly Technology Center in Indianapolis; as well as the acquisition and expansion of Lilly’s manufacturing site in Wisconsin.
Lilly selected the Pennsylvania location from over 300 proposals for its access to talent, infrastructure, and logistics critical for manufacturing facilities.
The Pennsylvania project is the fourth new US manufacturing site Lilly announced since February 2025. Construction is anticipated to begin in 2026, though the company did not provide additional details.
Manufacturing Emerges as a Top 2025 Construction Category
Lilly’s announcement follows a year of strong manufacturing construction starts, as it was among the top-performing categories in 2025 by percentage change.
This week, ConstructConnect Chief Economist Michael Guckes released a revised full-year chart of 2025 US Construction Starts for Select Subcategories.
The data showed Manufacturing rose 84.2 percent in 2025, following the top performer, Private Offices (Including Data Centers), which rose 110.9 percent.
A chart shows the revised Full Year 2025 US Construction Starts for Select Subcategories from the Construction Economy Snapshot. Image: ConstructConnect
Economic Impact Beyond the Build
The Lilly announcement carries implications for economic growth, local employment, and supply chain activity across the Lehigh Valley and Pennsylvania. Citing internal projections, Lilly expects its investment to drive up to $4 in local economic activity for each dollar spent on construction, operations, and partnerships.
For the broader region, Lilly’s presence is poised to help shape the life sciences sector, stimulate STEM-based education partnerships, and attract auxiliary business investment over the coming years.
Deploying Innovative Manufacturing Technologies
The new Pennsylvania facility will focus on advanced injectable therapies, including retatrutide, a candidate in the battle against obesity. To achieve this, Lilly plans to deploy innovative manufacturing technologies that integrate artificial intelligence, machine learning, and automated monitoring systems to maximize efficiency, quality, and reliability.
Such technological investments reflect a larger industry shift towards smart manufacturing, positioning the site as a model for future pharmaceutical facilities nationwide. This orientation toward innovation is likely to benefit not only patients awaiting next-gen treatments but also regional technology providers and workforce development programs.
State and Community Support
Lilly officials cited recent economic development initiatives, streamlined permitting, and targeted infrastructure investments as key drivers that made Pennsylvania, and the Lehigh Valley in particular, an attractive prospect.
The site’s proximity to universities and technical programs reflects a deliberate strategy to cultivate talent pipelines in coordination with industry leaders.
Lilly is a global pharmaceutical company that develops treatments for diabetes, obesity, Alzheimer’s, immune disorders, and cancer. The company statement emphasized its long-term commitment to operational excellence, environmental stewardship, and meaningful community partnerships.
This approach aligns with trends in major construction projects, where local engagement is a strategic initiative to support project success.
Stay Connected
Stay connected with ConstructConnect News, your source for construction economy insights, market trends, and project news.
About ConstructConnect
At ConstructConnect, our software solutions provide the information construction professionals need to start every project on a solid foundation. For more than 100 years, our insights and market intelligence have empowered commercial firms, manufacturers, trade contractors, and architects to make data-driven decisions and maximize productivity.
ConstructConnect is a business unit of Roper Technologies (Nasdaq: ROP), part of the Nasdaq 100, S&P 500, and Fortune 1000.
For more information, visit constructconnect.com
